Influenza B Infections Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 15, 2015 -- The report “Influenza B Infections – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Influenza B Infections. Influenza B is a type of flu that is similar to influenza A. influenza B can contaminate any time of the year. Influenza B flu is found only in humans. Influenza B is less ordinary but still causes outbreaks of seasonal flu. Influenza B is more serious in children. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/influenza-b-infections-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Influenza B Infections and special features on late-stage and discontinued projects. Companies discussed in this Influenza B Infections – Pipeline Review, H1 2015 report include AltraVax Inc., Chimerix, Inc., ContraFect Corporation, Crucell N.V., Humabs BioMed SA, REPLICor Inc.
Symptoms of Influenza B includes runny nose, sore throat, aching muscles, headache, cough, nasal congestion, malaise, fever, watery eyes, aching joints, sore throate, aching body, chills, ratigue, red eyes, red skin, red nose, red throat, loss of appetite and weakness. Drugs profile discussed in this report include AL-18, CF-403, CR-8033, CR-8071, CR-9114, Monoclonal Antibody for Influenza B Infections, REP-9, seasonal influenza B vaccine, Small Molecules for Influenza B. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269593 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this “Influenza B Infections – Pipeline Review, H1 2015” report include: Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine; Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children.
The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Table of content
List of Tables
Number of Products under Development for Influenza B Infections, H1 2015
Number of Products under Development for Influenza B Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Influenza B Infections - Pipeline by AltraVax Inc., H1 2015
Influenza B Infections - Pipeline by Chimerix, Inc., H1 2015
Influenza B Infections - Pipeline by ContraFect Corporation, H1 2015
Influenza B Infections - Pipeline by Crucell N.V., H1 2015
Influenza B Infections - Pipeline by Humabs BioMed SA, H1 2015
Influenza B Infections - Pipeline by REPLICor Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Influenza B Infections - Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Influenza B Infections, H1 2015
Number of Products under Development for Influenza B Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Explore more reports on Infectious Diseases Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, Rnrmarketresearch.com, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article